TG Therapeutics (NASDAQ:TGTX) Shares Up 4.8%

TG Therapeutics, Inc. (NASDAQ:TGTX) shares were up 4.8% during trading on Thursday . The company traded as high as $14.63 and last traded at $14.48. Approximately 1,638,056 shares traded hands during mid-day trading, a decline of 61% from the average daily volume of 4,168,954 shares. The stock had previously closed at $13.82.

Wall Street Analysts Forecast Growth

TGTX has been the subject of several research reports. JPMorgan Chase & Co. restated an “overweight” rating and set a $25.00 price objective on shares of TG Therapeutics in a research report on Thursday. The Goldman Sachs Group upped their price objective on TG Therapeutics from $12.00 to $13.00 and gave the company a “neutral” rating in a report on Thursday, February 29th. StockNews.com downgraded TG Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, February 24th. LADENBURG THALM/SH SH reaffirmed a “buy” rating and set a $39.00 price target on shares of TG Therapeutics in a research report on Thursday. Finally, HC Wainwright restated a “buy” rating and set a $45.00 target price on shares of TG Therapeutics in a research report on Thursday. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $29.00.

TG Therapeutics Price Performance

The company has a quick ratio of 5.18, a current ratio of 5.92 and a debt-to-equity ratio of 0.62. The stock has a market capitalization of $2.13 billion, a price-to-earnings ratio of 689.34 and a beta of 2.30. The business’s 50 day simple moving average is $15.11 and its 200-day simple moving average is $13.91.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.03. The company had revenue of $43.97 million during the quarter, compared to the consensus estimate of $40.06 million. TG Therapeutics had a net margin of 5.42% and a return on equity of 12.89%. During the same quarter in the prior year, the firm posted ($0.39) EPS. On average, research analysts forecast that TG Therapeutics, Inc. will post -0.12 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Laurence N. Charney sold 22,000 shares of TG Therapeutics stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $15.97, for a total value of $351,340.00. Following the transaction, the director now owns 215,229 shares in the company, valued at approximately $3,437,207.13. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 9.20% of the company’s stock.

Institutional Trading of TG Therapeutics

Several large investors have recently bought and sold shares of TGTX. Pingora Partners LLC acquired a new position in TG Therapeutics during the fourth quarter worth about $27,000. Coppell Advisory Solutions LLC bought a new stake in shares of TG Therapeutics during the 2nd quarter valued at approximately $46,000. Providence Capital Advisors LLC increased its position in TG Therapeutics by 1,403.9% during the 1st quarter. Providence Capital Advisors LLC now owns 1,910 shares of the biopharmaceutical company’s stock worth $127,000 after purchasing an additional 1,783 shares in the last quarter. KBC Group NV bought a new position in TG Therapeutics in the 4th quarter valued at approximately $54,000. Finally, PNC Financial Services Group Inc. lifted its stake in TG Therapeutics by 131.7% in the 3rd quarter. PNC Financial Services Group Inc. now owns 3,543 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 2,014 shares during the last quarter. 58.58% of the stock is owned by institutional investors and hedge funds.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.